Get the Stockscreener App
239.50
0.41%
-0.99
After Hours:
239.86
0.36
+0.15%
Penumbra Inc stock is traded at $239.50, with a volume of 300.19K.
It is down -0.41% in the last 24 hours and up +0.66% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
See More
Previous Close:
$240.49
Open:
$240.68
24h Volume:
300.19K
Relative Volume:
0.61
Market Cap:
$9.34B
Revenue:
$1.24B
Net Income/Loss:
$42.23M
P/E Ratio:
225.94
EPS:
1.06
Net Cash Flow:
$150.33M
1W Performance:
-0.37%
1M Performance:
+0.66%
6M Performance:
-10.73%
1Y Performance:
+40.86%
1-Day Range:
$236.66
$242.57
1-Week Range:
$234.34
$243.27
52-Week Range:
$168.30
$310.00
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
239.50 | 9.38B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
131.36 | 233.71B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.75 | 152.83B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
376.67 | 144.35B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.74 | 119.00B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.16 | 46.00B | 5.69B | 4.14B | 577.90M | 6.96 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra Inc. Breaks Losing Streak — Is the Trend ReversingWeekly Chart Analysis With Entry Advice Provided - metal.it
Aspiration Thrombectomy Device Market Set to Witness - openPR.com
What makes Penumbra Inc. stock price move sharplyEarly Entry Picks Before News Breakout Reviewed - metal.it
Penumbra Inc.: Thrombectomy Business Expansion As a Significant Driver For Overall Market Share Growth! - Smartkarma
MACD Signals Flash Warning for Penumbra Inc. StockOptimized Watchlist With Daily Adjustments Launched - metal.it
How volatile is Penumbra Inc. stock compared to the marketAchieve breakthrough growth with proven strategies - Jammu Links News
Is it the right time to buy Penumbra Inc. stockBreakthrough profits - Jammu Links News
What are analysts’ price targets for Penumbra Inc. in the next 12 monthsRapid return acceleration - Jammu Links News
How strong is Penumbra Inc. company’s balance sheetFree Bull & Bear Market Updates - Jammu Links News
Is Penumbra Inc. a growth stock or a value stockAccelerated capital growth - Jammu Links News
Penumbra Inc. Stock Analysis and ForecastInvest smarter with real-time trading alerts - Jammu Links News
What are the latest earnings results for Penumbra Inc.Spectacular growth rates - Jammu Links News
What is the risk reward ratio of investing in Penumbra Inc. stockDiscover investment plans that deliver results - Jammu Links News
What are Penumbra Inc. company’s key revenue driversRapid portfolio appreciation - Jammu Links News
What institutional investors are buying Penumbra Inc. stockFree Risk Assessment Services - Jammu Links News
Results: Penumbra, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Penumbra, Inc. Reports Second Quarter 2025 Financial Results - ADVFN Brasil
Penumbra price target raised to $325 from $316 at Baird - TipRanks
Penumbra's Strong Growth Potential and Strategic Developments Support Buy Rating with $327 Price Target - AInvest
UBS Analyst Increases Penumbra's Price Target to $335 - AInvest
Penumbra to Present at Canaccord Genuity 45th Annual Growth Conference - AInvest
Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference - Eastern Progress
Morgan Stanley Raises Price Target for Penumbra (PEN) to $266 | - GuruFocus
Should You Invest in Penumbra (PEN)? - Insider Monkey
Penumbra, Inc. (NYSE:PEN) Q2 2025 Earnings Call Transcript - Insider Monkey
Penumbra Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Penumbra outlines 13% to 15% revenue growth target for 2025 as thrombectomy adoption accelerates - MSN
Penumbra Inc. Reports Strong Q2 Earnings with Growth in U.S. Thrombectomy - TipRanks
Penumbra Surges 11.9% on Q2 Earnings Beat and Margin Expansion as $300M Volume Pushes It to 407th Trading Rank - AInvest
Penumbra (PEN) Q2 Revenue Jumps 13% - AOL.com
Penumbra (PEN) Shares Skyrocket, What You Need To Know - Yahoo Finance
Penumbra stock price target lowered to $325 at RBC Capital on margin outlook - Investing.com India
Penumbra: Truist Securities maintains a 'Buy' Rating, The Target Price is $310 - AInvest
Penumbra (PEN) Analyst Rating Update: Baird Raises Price Target - GuruFocus
Penumbra (PEN) Price Target Revised by RBC Capital | PEN Stock N - GuruFocus
Penumbra (PEN) Price Target Raised by Truist Following Earnings Beat - GuruFocus
Penumbra stock price target raised to $335 from $330 at UBS on solid growth - Investing.com
Penumbra (PEN) Price Target Raised by Baird to $285 - GuruFocus
Penumbra (PEN) Target Price Raised by Canaccord Genuity | PEN St - GuruFocus
Penumbra price target raised to $335 from $330 at UBS - TipRanks
Why Did Penumbra Stock Soar 14.46%? - AInvest
S&P 500 Futures Climb in Premarket Trading; Penumbra, Marvell Technology Lead - Barron's
Why Penumbra Inc. stock attracts strong analyst attentionScalable Portfolio Growth Suggestions Released - metal.it
Penumbra Inc (PEN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Penumbra Inc (PEN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Penumbra Inc (PEN) Q2 2025 Earnings Call Highlights: Strong Reve - GuruFocus
Penumbra, Inc. Reports Strong Q2 2025 Results - TipRanks
Penumbra 2025 Q2 Earnings Strong Performance as Net Income Swings to Profit - AInvest
Penumbra's Q2 2025: Dissecting Contradictions on Thunderbolt FDA Review, Revenue Guidance, and Market Dynamics - AInvest
Penumbra Lifts Revenue Forecast As US Demand Climbs - Finimize
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):